公开(公告)号：US20210040205A1

公开(公告)日：2021-02-11

申请号：US16758748

申请日：2018-10-23

Applicant: NOVARTIS AG

Inventor： Sunyoung JANG ,  Haihui LU ,  Matthew John MEYER ,  Ryan MOLONY ,  Karrie WONG

IPC: C07K16/28 ,  A61K47/68 ,  A61K45/06

Abstract: The present disclosure relates to anti-CD32b antibody molecules which selectively bind human CD32b. Also provided herein are compositions comprising anti-CD32b antibody molecules in combination with other compounds, and methods of using the combinations to treat subject with cancer.

公开(公告)号：US20240025993A1

公开(公告)日：2024-01-25

申请号：US18035470

申请日：2021-11-04

Applicant: NOVARTIS AG

Inventor： Regis CEBE ,  Dattananda CHELUR ,  Brian Walter GRANDA ,  Connie WONG ,  Sunyoung JANG ,  Haihui LU ,  Amy RAYO ,  Darko SKEGRO

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2803 ,  A61P35/00 ,  C07K2317/565 ,  C07K2317/52 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/622 ,  C07K2317/55

Abstract: The present disclosure provides CD19 binding molecules that specifically bind to CD19, including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD19 binding molecules, and pharmaceutical compositions comprising the CD19 binding molecules and the conjugates. The disclosure further provides methods of using the C19 binding molecules to treat diseases and disorders associated with expression of CD19. The disclosure yet further provides recombinant host cells engineered to express the CD19 binding molecules and methods of producing the CD19 binding molecules by culturing the host cells under conditions in which the CD19 binding molecules are expressed.